I agree that this site is using cookies. You can find further informations
here
.
X
Login
Merkliste (
0
)
Home
About us
Home About us
Our history
Profile
Press & public relations
Friends
The library in figures
Exhibitions
Projects
Training, internships, careers
Films
Services & Information
Home Services & Information
Lending and interlibrary loans
Returns and renewals
Training and library tours
My Account
Library cards
New to the library?
Download Information
Opening hours
Learning spaces
PC, WLAN, copy, scan and print
Catalogs and collections
Home Catalogs and Collections
Rare books and manuscripts
Digital collections
Subject Areas
Our sites
Home Our sites
Central Library
Law Library (Juridicum)
BB Business and Economics (BB11)
BB Physics and Electrical Engineering
TB Engineering and Social Sciences
TB Economics and Nautical Sciences
TB Music
TB Art & Design
TB Bremerhaven
Contact the library
Home Contact the library
Staff Directory
Open access & publishing
Home Open access & publishing
Reference management: Citavi & RefWorks
Publishing documents
Open Access in Bremen
zur Desktop-Version
Toggle navigation
Merkliste
1 Ergebnisse
1
The efficacy and safety of first-line treatment in cisplati..:
Jiwei Huang
;
Ruopeng Su
;
Zeyu Chen
...
https://www.tandfonline.com/doi/10.1080/2162402X.2022.2124691. , 2022
Link:
https://doi.org/10.1080/2162402X.2022.2124691
RT Journal T1
The efficacy and safety of first-line treatment in cisplatin-ineligible advanced upper tract urothelial carcinoma patients: a comparison of PD-1 inhibitor and carboplatin plus gemcitabine chemotherapy
UL https://suche.suub.uni-bremen.de/peid=base-ftdoajarticles:oai:doaj.org_article:1bb537d63a744684b3f442e300063de3&Exemplar=1&LAN=DE A1 Jiwei Huang A1 Ruopeng Su A1 Zeyu Chen A1 Shuai Jiang A1 Minfeng Chen A1 Yichu Yuan A1 Hailong Hu A1 Changde Fu A1 Zhiyang Huang A1 Zhenyu Wang A1 Bing Zheng A1 Chancan Li A1 Zaoyu Wang A1 Yige Bao A1 Ming Cai A1 Jianming Guo A1 Qiang Wei A1 Wei Xue PB Taylor & Francis Group YR 2022 K1 Upper tract urothelial carcinoma K1 PD-1 inhibitor K1 carboplatin K1 Cisplatin-ineligible K1 Immunologic diseases. Allergy K1 RC581-607 K1 Neoplasms. Tumors. Oncology. Including cancer and carcinogens K1 RC254-282 JF https://www.tandfonline.com/doi/10.1080/2162402X.2022.2124691 LK http://dx.doi.org/https://doi.org/10.1080/2162402X.2022.2124691 DO https://doi.org/10.1080/2162402X.2022.2124691 SF ELIB - SuUB Bremen
Export
RefWorks (nur Desktop-Version!)
Flow
(Zuerst in
Flow
einloggen, dann importieren)